サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795252

ヤヌスキナーゼ（JAK）阻害剤の世界市場

Janus Kinase (JAK) Inhibitors

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ヤヌスキナーゼ（JAK）阻害剤の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヤヌスキナーゼ（JAK）阻害剤の世界市場は2030年までに327億米ドルに達する見込み

2024年に117億米ドルと推定されるヤヌスキナーゼ（JAK）阻害剤の世界市場は、2024～2030年の分析期間においてCAGR 18.6%で成長し、2030年には327億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである自己免疫疾患アプリケーションは、CAGR 20.7％を記録し、分析期間終了までに229億米ドルに達すると予測されます。オンコロジーアプリケーションセグメントの成長率は、分析期間中CAGR 14.7%と推定されます。

米国市場は32億米ドルと推定、中国はCAGR 25.6％で成長予測

米国のヤヌスキナーゼ（JAK）阻害剤市場は2024年に32億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに77億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは25.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.6%と16.8%と予測されています。欧州では、ドイツがCAGR約15.6%で成長すると予測されています。

世界のヤヌスキナーゼ（JAK）阻害剤市場- 主要動向と促進要因のまとめ

ヤヌスキナーゼ阻害剤が炎症性疾患および自己免疫疾患の治療に革命をもたらす理由とは？

ヤヌスキナーゼ（JAK）阻害剤は、その標的作用機序、迅速な症状コントロール、経口投与が可能なことから、広範囲の慢性炎症性疾患および自己免疫疾患の管理において、変革的な治療選択肢として急速に台頭してきました。これらの低分子薬剤は、関節リウマチ、乾癬性関節炎、潰瘍性大腸炎、アトピー性皮膚炎、強直性脊椎炎などの疾患の病因の中心であるサイトカインを介する細胞内シグナル伝達経路を遮断します。JAK-STATシグナル伝達カスケードを調節することにより、JAK阻害剤は、コルチコステロイドや従来の疾患修飾性抗リウマチ薬（DMARDs）に伴う広範な免疫抑制作用を伴わずに、免疫の過剰活性を抑制することができます。また、経口投与は、生物学的製剤の注射剤に代わる魅力的な選択肢であり、患者のアドヒアランスと利便性を向上させる。臨床医は、JAK阻害剤を難治性の患者や既存の生物学的製剤で十分な効果が得られない患者に対する貴重な選択肢と考えるようになってきています。さらに、これらの治療薬の多くは迅速な作用発現を示し、数日から数週間で症状を緩和します。円形脱毛症や白斑などの新しい適応症に対する薬事承認は、この薬剤クラスの臨床的足跡が拡大していることをさらに強調しています。ライフスタイルの変化や環境要因、診断率の向上により、慢性的な自己免疫疾患が世界的に増加する中、JAK阻害剤の役割は、フロントラインおよびセカンドライン治療戦略の双方において、ますます中心的なものとなりつつあります。

分子標的および製剤の革新はJAK阻害剤治療の進化をどのように促しているのか？

JAK阻害剤を取り巻く科学的状況は、研究者が選択性を改良し、安全性プロファイルを向上させ、治療適応の範囲を拡大するにつれて急速に進化しています。JAK阻害剤の初期世代は、複数のJAKアイソフォームを同時に標的とする汎阻害剤であったため、標的外作用や感染症に対する懸念がありました。しかし、最近の開発の波は、JAK1、JAK2、TYK2のいずれかを優先的に標的とするアイソフォーム特異的阻害剤に集中しており、血栓塞栓合併症や脂質異常症などの有害事象の軽減を目指しています。製薬会社は、より高い結合精度と代謝安定性を持つ化合物を創製するために、高度な分子モデリングと構造に基づく薬剤設計を採用しています。薬物動態を改善し、1日1回あるいは週1回の投与レジメンを可能にするために、徐放性製剤や二重作用分子が研究されています。JAK阻害薬と生物学的製剤や従来のDMARDsを組み合わせた併用療法は、複雑な症例における有効性を改善するために臨床評価中です。さらに、全身への曝露を減らし局所的な治療を可能にする皮膚科疾患用の外用剤も開発されています。コンパニオン診断や薬理ゲノム解析ツールも臨床ワークフローに組み込まれつつあり、遺伝子プロファイルや疾患バイオマーカーに基づいて患者により適切なJAK阻害剤を選択できるようになっています。強力な臨床パイプラインには、ループス、多発性硬化症、移植片対宿主病、1型糖尿病などの治療困難な疾患に対する候補が含まれています。これらの技術革新は、治療成績を向上させるだけでなく、潜在的な患者層を拡大し、JAK阻害剤が精密免疫療法の要としての地位を強固なものにしています。

規制動向と安全性への懸念はJAK阻害剤の商業的展望にどのように影響するか？

規制当局は、JAK阻害剤の商業的および臨床的軌道を形成する上で重要な役割を担っており、特に、市販後の長期調査において安全性に関する懸念が顕在化した場合に重要です。米国FDA、EMA、その他の保健当局は、特定のJAK阻害剤で治療された患者における心血管イベント、悪性腫瘍、重篤な感染症の増加のシグナルを受け、監視を強化してきました。その結果、医薬品の添付文書に警告と適応の制限が追加され、処方の指針となるリスク評価・軽減戦略（REMS）が導入されました。こうした規制当局の対応により、製薬会社はより広範な集団における患者の安全性を監視するため、実臨床試験や承認後の登録に多額の投資を行うようになりました。これと並行して、支払者は償還基準をより選別するようになっており、特に低コストの生物製剤やバイオシミラーが利用可能な場合には、保険適用を承認する前に優れたベネフィット・リスク・プロファイルのエビデンスを要求しています。このようなハードルにもかかわらず、他の治療法に反応しない、あるいは不耐容の患者集団におけるJAK阻害剤の治療的価値により、需要は依然として旺盛です。現在、市場参入戦略には、ヘルスケア専門家向けの教育プログラム、デジタル・アドヒアランス・ツール、情報に基づいた意思決定を支援するためのアドボカシー団体との提携などが含まれることが多いです。さらに、地域的な規制の相違が世界の商業化の取り組みに影響を与えており、生物製剤へのアクセスが制限されている一部の新興市場では、より迅速な承認と幅広い適応が認められています。安全性については課題があるもの、より安全で選択性の高い化合物を製造し、JAK阻害剤を従来の免疫抑制剤や新しい生物学的製剤と差別化するための業界の技術革新も促進されています。

JAK阻害剤の世界市場の継続的成長を促進する要因は何か？

ヤヌスキナーゼ（JAK）阻害剤市場の成長は、臨床的、技術的、経済的、人口統計的な次元にまたがるいくつかの相互に関連する要因によって牽引されています。自己免疫疾患や慢性炎症性疾患の有病率が上昇し、特に高齢化社会と先進工業国において、JAK標的治療の対象となる患者層が拡大しています。患者が注射薬よりも経口薬を好むようになったことで、医師は特に長期治療を必要とする患者に対してJAK阻害薬をより頻繁に処方するようになっています。医薬品の技術革新により、薬剤の安全性、有効性、忍容性が継続的に向上しており、その結果、差別化されたプロファイルを有する次世代のJAK阻害剤のパイプラインが着実に構築されています。皮膚科、消化器科、希少自己免疫疾患への適応拡大により、複数の専門領域で製品の有用性が高まっています。競合力学も市場拡大に寄与しています。バイオシミラーやジェネリック医薬品が価格引き下げ圧力をかけ、中所得地域でも治療薬が入手しやすくなっているからです。医師の意識の向上、診断ツールの改善、疾患分類の改善により、JAK阻害剤のような標的治療による早期介入が可能となっています。より低いコストで成果を出す必要に迫られている医療システムは、入院、手術、長期合併症の減少におけるこれらの薬剤の価値を認識しています。支払者モデルは、患者報告によるアウトカムが証明された即効性のある治療法を優遇し、実世界での有効性に報いるように進化しています。免疫学研究への世界の投資と、より多様な人々を対象とした臨床試験の分散化が相まって、技術革新と市場参入が加速しています。これらの複合的な力により、JAK阻害剤は製薬業界の高成長セグメントであり続け、世界中の医薬品開発企業の収益機会を促進しながら、患者の緊急ニーズに応えています。

セグメント

アプリケーション（自己免疫疾患アプリケーション、がんアプリケーション）

調査対象企業の例

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celon Pharma S.A.
  • Confluence Life Sciences, Inc.
  • CTI BioPharma Corp.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Jiangsu Hengrui Pharmaceuticals Co.
  • Pfizer Inc.
  • Prometheus Biosciences, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sierra Oncology, Inc.
  • Sino Biopharmaceutical Limited
  • SOTIO Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Tiziana Life Sciences Ltd

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37225

Global Janus Kinase (JAK) Inhibitors Market to Reach US$32.7 Billion by 2030

The global market for Janus Kinase (JAK) Inhibitors estimated at US$11.7 Billion in the year 2024, is expected to reach US$32.7 Billion by 2030, growing at a CAGR of 18.6% over the analysis period 2024-2030. Autoimmune Disorders Application, one of the segments analyzed in the report, is expected to record a 20.7% CAGR and reach US$22.9 Billion by the end of the analysis period. Growth in the Oncology Application segment is estimated at 14.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 25.6% CAGR

The Janus Kinase (JAK) Inhibitors market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 25.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.6% CAGR.

Global Janus Kinase (JAK) Inhibitors Market - Key Trends & Drivers Summarized

Why Are Janus Kinase Inhibitors Revolutionizing the Management of Inflammatory and Autoimmune Diseases?

Janus kinase (JAK) inhibitors have rapidly emerged as a transformative therapeutic option in the management of a broad range of chronic inflammatory and autoimmune conditions due to their targeted mechanism of action, rapid symptom control, and oral availability. These small-molecule drugs interrupt intracellular signaling pathways mediated by cytokines, which are central to the pathogenesis of disorders like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and ankylosing spondylitis. By modulating the JAK-STAT signaling cascade, JAK inhibitors can downregulate immune overactivity without the broad immunosuppressive effects associated with corticosteroids or traditional disease-modifying antirheumatic drugs (DMARDs). Their oral administration also offers an appealing alternative to injectable biologics, improving adherence and convenience for patients. Clinicians increasingly view JAK inhibitors as a valuable option for patients with refractory disease or those who fail to respond adequately to existing biologics. Additionally, many of these therapies demonstrate rapid onset of action, providing symptom relief within days or weeks, which is crucial for improving quality of life and reducing disability. Regulatory approvals for newer indications such as alopecia areata and vitiligo further underscore the expanding clinical footprint of this drug class. With chronic autoimmune conditions rising globally due to lifestyle changes, environmental factors, and improved diagnosis rates, the role of JAK inhibitors is becoming increasingly central in both frontline and second-line treatment strategies.

How Is Innovation in Molecular Targeting and Formulation Driving the Evolution of JAK Inhibitor Therapies?

The scientific landscape surrounding JAK inhibitors is evolving rapidly as researchers refine selectivity, enhance safety profiles, and expand the scope of therapeutic indications. Initial generations of JAK inhibitors were pan-inhibitors, targeting multiple JAK isoforms simultaneously, which raised concerns about off-target effects and infections. However, the latest wave of development focuses on isoform-specific inhibitors that preferentially target JAK1, JAK2, or TYK2, aiming to reduce adverse events such as thromboembolic complications and lipid abnormalities. Pharmaceutical companies are employing advanced molecular modeling and structure-based drug design to create compounds with greater binding precision and metabolic stability. Extended-release formulations and dual-action molecules are being explored to improve pharmacokinetics and allow once-daily or even weekly dosing regimens. Combination therapies that pair JAK inhibitors with biologics or conventional DMARDs are under clinical evaluation to improve efficacy in complex cases. Additionally, topical formulations are being developed for dermatological conditions, allowing localized treatment with reduced systemic exposure. Companion diagnostics and pharmacogenomic tools are also being integrated into clinical workflows to better match patients with the most appropriate JAK inhibitor based on genetic profiles and disease biomarkers. The robust clinical pipeline includes candidates for hard-to-treat conditions such as lupus, multiple sclerosis, graft-versus-host disease, and type 1 diabetes. These innovations are not only improving therapeutic outcomes but also expanding the potential patient base, reinforcing JAK inhibitors’ position as a cornerstone of precision immunotherapy.

How Do Regulatory Trends and Safety Concerns Influence the Commercial Outlook for JAK Inhibitors?

Regulatory agencies play a critical role in shaping the commercial and clinical trajectory of JAK inhibitors, particularly as safety concerns emerge in long-term post-marketing surveillance. The US FDA, EMA, and other health authorities have implemented heightened scrutiny following signals of increased cardiovascular events, malignancies, and serious infections in patients treated with certain JAK inhibitors. As a result, boxed warnings and restricted indications have been added to drug labels, and risk evaluation and mitigation strategies (REMS) have been introduced to guide prescribing practices. These regulatory responses have prompted pharmaceutical companies to invest heavily in real-world evidence studies and post-approval registries to monitor patient safety across broader populations. In parallel, payers are becoming more selective in their reimbursement criteria, requiring evidence of superior benefit-risk profiles before approving coverage, especially when lower-cost biologics or biosimilars are available. Despite these hurdles, demand remains strong due to the therapeutic value of JAK inhibitors in patient populations that are non-responsive or intolerant to other therapies. Market access strategies now often include education programs for healthcare professionals, digital adherence tools, and partnerships with advocacy groups to support informed decision-making. Additionally, regional regulatory divergence is influencing global commercialization efforts, with faster approvals and broader indications granted in some emerging markets where access to biologics is limited. While the safety narrative presents a challenge, it is also catalyzing industry innovation to produce safer, more selective compounds and to differentiate JAK inhibitors from both traditional immunosuppressants and newer biologics.

What Factors Are Driving the Continued Growth of the Global JAK Inhibitors Market?

The growth in the Janus kinase (JAK) inhibitors market is driven by several interrelated factors spanning clinical, technological, economic, and demographic dimensions. Rising prevalence of autoimmune and chronic inflammatory conditions, particularly in aging populations and industrialized nations, is expanding the eligible patient pool for JAK-targeted therapies. Patient preference for oral medications over injectables is pushing physicians to prescribe JAK inhibitors more frequently, especially for individuals requiring long-term treatment. Pharmaceutical innovation is continuously enhancing drug safety, efficacy, and tolerability, resulting in a steady pipeline of next-generation JAK inhibitors with differentiated profiles. Expanding label approvals into dermatology, gastroenterology, and rare autoimmune diseases are increasing product utility across multiple specialties. Competitive dynamics are also contributing to market expansion, as biosimilars and generic alternatives place downward pressure on pricing, making therapies more accessible in middle-income regions. Increased physician awareness, better diagnostic tools, and improved disease classification are enabling earlier intervention with targeted treatments like JAK inhibitors. Health systems under pressure to deliver outcomes at lower costs are recognizing the value of these drugs in reducing hospitalization, surgeries, and long-term complications. Payer models are evolving to reward real-world effectiveness, which favors fast-acting therapies with proven patient-reported outcomes. Global investment in immunology research, combined with the decentralization of clinical trials to reach more diverse populations, is accelerating innovation and market reach. These combined forces are ensuring that JAK inhibitors will remain a high-growth segment of the pharmaceutical industry, meeting the urgent needs of patients while driving revenue opportunities for drug developers worldwide.

SCOPE OF STUDY:

The report analyzes the Janus Kinase (JAK) Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Autoimmune Disorders Application, Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celon Pharma S.A.
  • Confluence Life Sciences, Inc.
  • CTI BioPharma Corp.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Jiangsu Hengrui Pharmaceuticals Co.
  • Pfizer Inc.
  • Prometheus Biosciences, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sierra Oncology, Inc.
  • Sino Biopharmaceutical Limited
  • SOTIO Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Tiziana Life Sciences Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Janus Kinase (JAK) Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Autoimmune Disease Prevalence Propels Growth of JAK Inhibitor Therapeutics
    • Shift Toward Targeted Small Molecule Therapies Strengthens Business Case for JAK Inhibition
    • Advancements in Immunology Research Throw the Spotlight on JAK Pathway as a Drug Target
    • Increasing Adoption in Dermatological Indications Accelerates Demand for Topical and Oral JAK Inhibitors
    • Pipeline Diversification in Oncology Expands Addressable Market for Next-Generation JAK Inhibitors
    • Favorable Clinical Outcomes in Rheumatoid Arthritis Drive Adoption Across Autoimmune Segments
    • Payer Pressure and Cost Sensitivities Spur Interest in Oral JAK Inhibitors Over Biologics
    • Patient Preference for Oral Administration Sustains Growth in Chronic Disease Management
    • Biomarker-Guided Therapy Development Throws the Spotlight on Personalized JAK Inhibitor Strategies
    • Expanding Geriatric Population Drives Demand for Convenient, Long-Term Immunomodulation Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Janus Kinase (JAK) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • CHINA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • INDIA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030

IV. COMPETITION